Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00117540" target="_blank" >RIV/00216224:14110/19:00117540 - isvavai.cz</a>
Result on the web
<a href="https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core" target="_blank" >https://ashpublications.org/blood/article/134/Supplement_1/2693/423109/Characteristics-and-Outcome-of-Patients-with-Core</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood-2019-125317" target="_blank" >10.1182/blood-2019-125317</a>

Result language
angličtina
Original language name
Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration
Original language description
Core binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22) and is associated with a favorable outcome, particularly if treated with repetitive cycles of high-dose cytarabine as post-remission therapy. Long-time 10-year overall survival (OS) rate was reported of 58% in FLT3-ITD negative patients (pts; Allen et al. Leukemia 2013). Nevertheless, 30-40% CBF-AML pts experience relapse. FLT3-ITD mutations occur in roughly 5-10% of adult CBF-AML. However, their prognostic relevance is still controversial.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)